X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs CADILA HEALTHCARE - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB CADILA HEALTHCARE DR. REDDYS LAB/
CADILA HEALTHCARE
 
P/E (TTM) x 27.7 18.5 149.9% View Chart
P/BV x 3.4 4.2 81.5% View Chart
Dividend Yield % 0.8 1.0 78.9%  

Financials

 DR. REDDYS LAB   CADILA HEALTHCARE
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
CADILA HEALTHCARE
Mar-18
DR. REDDYS LAB/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs2,788558 499.6%   
Low Rs1,902362 526.1%   
Sales per share (Unadj.) Rs860.8116.3 740.2%  
Earnings per share (Unadj.) Rs57.117.9 319.4%  
Cash flow per share (Unadj.) Rs122.023.1 527.4%  
Dividends per share (Unadj.) Rs20.003.50 571.4%  
Dividend yield (eoy) %0.90.8 112.0%  
Book value per share (Unadj.) Rs757.785.4 887.1%  
Shares outstanding (eoy) m165.911,023.74 16.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.74.0 68.9%   
Avg P/E ratio x41.125.7 159.7%  
P/CF ratio (eoy) x19.219.9 96.7%  
Price / Book Value ratio x3.15.4 57.5%  
Dividend payout %35.019.6 178.9%   
Avg Mkt Cap Rs m389,034470,664 82.7%   
No. of employees `00023.511.8 199.0%   
Total wages/salary Rs m32,14918,545 173.4%   
Avg. sales/employee Rs Th6,070.810,072.7 60.3%   
Avg. wages/employee Rs Th1,366.61,569.1 87.1%   
Avg. net profit/employee Rs Th402.51,547.7 26.0%   
INCOME DATA
Net Sales Rs m142,810119,049 120.0%  
Other income Rs m1,5521,132 137.1%   
Total revenues Rs m144,362120,181 120.1%   
Gross profit Rs m23,51228,475 82.6%  
Depreciation Rs m10,7725,388 199.9%   
Interest Rs m788911 86.5%   
Profit before tax Rs m13,50423,308 57.9%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3805,644 77.6%   
Profit after tax Rs m9,46818,292 51.8%  
Gross profit margin %16.523.9 68.8%  
Effective tax rate %32.424.2 133.9%   
Net profit margin %6.615.4 43.1%  
BALANCE SHEET DATA
Current assets Rs m104,98482,005 128.0%   
Current liabilities Rs m68,93860,720 113.5%   
Net working cap to sales %25.217.9 141.2%  
Current ratio x1.51.4 112.8%  
Inventory Days Days7473 101.7%  
Debtors Days Days10498 105.4%  
Net fixed assets Rs m104,38583,703 124.7%   
Share capital Rs m8301,024 81.1%   
"Free" reserves Rs m124,88686,421 144.5%   
Net worth Rs m125,71687,445 143.8%   
Long term debt Rs m25,08925,551 98.2%   
Total assets Rs m225,443180,653 124.8%  
Interest coverage x18.126.6 68.2%   
Debt to equity ratio x0.20.3 68.3%  
Sales to assets ratio x0.60.7 96.1%   
Return on assets %4.510.6 42.8%  
Return on equity %7.520.9 36.0%  
Return on capital %9.722.0 44.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62342,683 170.1%   
Fx outflow Rs m18,91611,242 168.3%   
Net fx Rs m53,70731,441 170.8%   
CASH FLOW
From Operations Rs m18,0309,193 196.1%  
From Investments Rs m-14,883-9,737 152.8%  
From Financial Activity Rs m-4,440515 -862.1%  
Net Cashflow Rs m-1,236-29 4,262.1%  

Share Holding

Indian Promoters % 25.5 74.8 34.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.3 65.1%  
FIIs % 35.3 5.9 598.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 11.0 139.1%  
Shareholders   75,885 44,069 172.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  MERCK LTD  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

WOCKHARDT LTD. Surges by 7%; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Nov 21, 2018 | Updated on Nov 21, 2018

WOCKHARDT LTD. share price has surged by 7% and its current market price is Rs 555. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT LTD. (up 7.0%) and DR. REDDYS LAB (up 7.2%). The top losers are TORRENT PHARMA and FORTIS HEALTHCARE (down 0.1%).

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 21, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS